<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>METHYLERGONOVINE MALEATE - methylergonovine maleate injection, solution </strong><br>American Regent, Inc.<br></p></div>
<h1>Methylergonovine Maleate Injection, USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1><span class="Bold">DESCRIPTION</span></h1>
<p class="First">Methylergonovine maleate is a semi-synthetic ergot alkaloid used for the prevention and control of <span class="product-label-link" type="condition" conceptid="443929" conceptname="Postpartum hemorrhage">postpartum hemorrhage</span>.</p>
<p>Methylergonovine maleate injection is a clear, colorless, sterile solution available in 1 mL single dose vials, containing methylergonovine maleate 0.2 mg for intramuscular or intravenous injection.</p>
<p><span class="Italics">Active Ingredient</span>: methylergonovine maleate 0.2 mg.</p>
<p><span class="Italics">Inactive Ingredients:</span>maleic acid 0.10 mg; sodium chloride 7.0 mg; water for injection qs to 1 mL.</p>
<p>Chemically, methylergonovine maleate is designated as ergoline-8-carboxamide, 9,10-didehydro-<span class="Italics">N</span>-[1-(hydroxymethyl)propyl]-6-methyl-,[8β(<span class="Italics">S</span>)]-, (<span class="Italics">Z</span>)-2-butenedioate (1:1) (salt).</p>
<p>Its structural formula is:</p>
<div class="Figure"><img alt="08d60c14-figure-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a9a3079e-b62b-4858-920e-d8f5cb38481e&amp;name=08d60c14-figure-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY</span></h1>
<p class="First">Methylergonovine maleate acts directly on the smooth muscle of the uterus and increases the tone, rate, and amplitude of rhythmic contractions.  Thus, it induces a rapid and sustained tetanic uterotonic effect which shortens the third stage of labor and reduces blood loss.  The onset of action after intravenous administration is immediate; after intramuscular administration, 2 to 5 minutes, and after oral administration, 5 to 10 minutes.</p>
<p>Pharmacokinetic studies following an intravenous injection have shown that methylergonovine is rapidly distributed from plasma to peripheral tissues within 2 to 3 minutes or less.  The bioavailability after oral administration was reported to be about 60% with no accumulation after repeated doses.  During delivery, with intramuscular injection, bioavailability increased to 78%.  Ergot alkaloids are mostly eliminated by hepatic metabolism and excretion, and the decrease in bioavailability following oral administration is probably a result of first-pass metabolism in the liver.</p>
<p>Bioavailability studies conducted in fasting healthy female volunteers have shown that oral absorption of a 0.2 mg methylergonovine tablet was fairly rapid with a mean peak plasma concentration of 3243 ± 1308 pg/mL observed at 1.12 ± 0.82 hours.  For a 0.2 mg intramuscular injection, a mean peak plasma concentration of 5918 ± 1952 pg/mL was observed at 0.41 ± 0.21 hours.  The extent of absorption of the tablet, based upon methylergonovine plasma concentrations, was found to be equivalent to that of the intramuscular solution given orally, and the extent of oral absorption of the intramuscular solution was proportional to the dose following administration of 0.1, 0.2, and 0.4 mg.  When given intramuscularly, the extent of absorption of methylergonovine maleate solution was about 25% greater than the tablet.  The volume of distribution (Vd<span class="Sub">ss</span>/F) of methylergonovine was calculated to be 56.1 ± 17.0 liters, and the plasma clearance (CLp/F) was calculated to be 14.4 ± 4.5 liters per hour.  The plasma level decline was biphasic with a mean elimination half-life of 3.39 hours (range 1.5 to 12.7 hours).  A delayed gastrointestinal absorption (T<span class="Sub">max</span>about 3 hours) of methylergonovine maleate tablet might be observed in postpartum women during continuous treatment with this oxytocic agent.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="b45816f4-80f3-4bb4-908b-6125161aa7e0"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE</span></h1>
<p class="First">Following delivery of the placenta, for routine management of <span class="product-label-link" type="condition" conceptid="4127206" conceptname="Uterus relaxed">uterine atony</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> and subinvolution of the uterus.  For control of <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine hemorrhage</span> in the second stage of labor following delivery of the anterior shoulder.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS</span></h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>; toxemia; pregnancy; and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="b4122711-1141-4132-8ab3-e589472a8204"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">WARNINGS</span></h1>
<div class="Section">
<a name="section-5.1"></a><p></p>
<h2><span class="Bold">General</span></h2>
<p class="First">This drug should not be administered intravenously routinely because of the possibility of inducing sudden hypertensive and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accidents</span>.  If intravenous administration is considered essential as a lifesaving measure, methylergonovine maleate should be given slowly over a period of no less than 60 seconds with careful monitoring of blood pressure.  Intra-arterial or periarterial injection should be strictly avoided.</p>
<p>Caution should be exercised in the presence of impaired hepatic or renal function.</p>
</div>
<div class="Section">
<a name="section-5.2"></a><p></p>
<h2><span class="Bold">Breast-feeding</span></h2>
<p class="First">Mothers should not breast-feed during treatment with methylergonovine maleate. Milk secreted during this period should be discarded. Methylergonovine maleate may produce adverse effects in the breast-feeding infant. Methylergonovine maleate may also reduce the yield of breast milk. Mothers should wait at least 12 hours after administration of the last dose of methylergonovine maleate before initiating or resuming breast feeding.</p>
</div>
<div class="Section">
<a name="section-5.3"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">Coronary artery disease</span></span></h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> or risk factors for <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span> (e.g., smoking, <span class="product-label-link" type="condition" conceptid="433736" conceptname="Obesity">obesity</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, high <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>) may be more susceptible to developing <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> and <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> associated with methylergonovine-induced <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>.</p>
</div>
<div class="Section">
<a name="section-5.4"></a><p></p>
<h2><span class="Bold">Medication errors</span></h2>
<p class="First">Inadvertent administration of methylergonovine maleate to newborn infants has been reported. In these cases of inadvertent neonatal exposure, symptoms such as <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span> and <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> have been reported. Usual treatment is symptomatic. However, in severe cases, respiratory and cardiovascular support is required.</p>
<p>Methylergonovine maleate has been administered instead of vitamin K and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span> B vaccine, medications which are routinely administered to the newborn. Due to the potential for accidental neonatal exposure, methylergonovine maleate injection should be stored separately from medications intended for neonatal administration.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1><span class="Bold">PRECAUTIONS</span></h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-6.1"></a><p></p>
<h2><span class="Bold">General</span></h2>
<p class="First">Caution should be exercised in the presence of <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> or obliterative vascular disease.  Also use with caution during the second stage of labor.  The necessity for manual removal of a <span class="product-label-link" type="condition" conceptid="4003030" conceptname="Retained placenta">retained placenta</span> should occur only rarely with proper technique and adequate allowance of time for its spontaneous separation.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-6.2"></a><p></p>
<h2><span class="Bold">Drug Interactions</span></h2>
<div class="Section">
<a name="section-6.2.1"></a><p></p>
<h3><span class="Italics">CYP3A4 Inhibitors (e.g., Macrolide Antibiotics and Protease Inhibitors)</span></h3>
<p class="First">There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g., dihydroergotamine and ergotamine) and potent CYP3A4 inhibitors, resulting in <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> leading to <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the extremities.  Although there have been no reports of such interactions with methylergonovine alone, potent CYP3A4 inhibitors should not be coadministered with methylergonovine.  Examples of some of the more potent CYP3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).  Less potent CYP3A4 inhibitors should be administered with caution.  Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.  These lists are not exhaustive, and the prescriber should consider the effects on CYP3A4 of other agents being considered for concomitant use with methylergonovine.</p>
</div>
<div class="Section">
<a name="section-6.2.2"></a><p></p>
<h3><span class="Italics">CYP3A4 inducers</span></h3>
<p class="First">Drugs (e.g., nevirapine, rifampicin) that are strong inducers of CYP3A4 are likely to decrease the pharmacological action of methylergonovine maleate.</p>
</div>
<div class="Section">
<a name="section-6.2.3"></a><p></p>
<h3><span class="Italics">Beta-blockers</span></h3>
<p class="First">Caution should be exercised when methylergonovine maleate is used concurrently with beta-blockers. Concomitant administration with beta-blockers may enhance the vasoconstrictive action of ergot alkaloids.</p>
</div>
<div class="Section">
<a name="section-6.2.4"></a><p></p>
<h3><span class="Italics">Anesthetics</span></h3>
<p class="First">Anesthetics like halothane and methoxyflurane may reduce the oxytocic potency of methylergonovine maleate.</p>
</div>
<div class="Section">
<a name="section-6.2.5"></a><p></p>
<h3><span class="Italics">Glyceryl trinitrate and other antianginal drugs</span></h3>
<p class="First">Methylergonovine maleate produces <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span> and can be expected to reduce the effect of glyceryl trinitrate and other antianginal drugs.</p>
<p>No <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> involving other cytochrome P450 isoenzymes are known.</p>
<p>Caution should be exercised when methylergonovine maleate is used concurrently with other vasoconstrictors, ergot alkaloids, or prostaglandins.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-6.3"></a><p></p>
<h2><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</span></h2>
<p class="First">No long-term studies have been performed in animals to evaluate carcinogenic potential.  The effect of the drug on mutagenesis or fertility has not been determined.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-6.4"></a><p></p>
<h2><span class="Bold">Pregnancy</span></h2>
<p class="First"><span class="Bold Italics">Category C. </span>Animal reproductive studies have not been conducted with methylergonovine maleate.  It is also not known whether methylergonovine maleate can cause fetal harm or can affect reproductive capacity.  Use of methylergonovine maleate is contraindicated during pregnancy because of its uterotonic effects.  (See<a href="#b45816f4-80f3-4bb4-908b-6125161aa7e0">INDICATIONS AND USAGE</a>.)</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-6.5"></a><p></p>
<h2><span class="Bold">Labor and Delivery</span></h2>
<p class="First">The uterotonic effect of methylergonovine maleate is utilized after delivery to assist involution and decrease <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, shortening the third stage of labor.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-6.6"></a><p></p>
<h2><span class="Bold">Nursing Mothers</span></h2>
<p class="First">Mothers should not breast-feed during treatment with methylergonovine maleate and for at least 12 hours after administration of the last dose. Milk secreted during this period should be discarded.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-6.7"></a><p></p>
<h2><span class="Bold">Pediatric Use</span></h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-6.8"></a><p></p>
<h2><span class="Bold">Geriatric Use</span></h2>
<p class="First">Clinical studies of methylergonovine maleate did not include a sufficient number of subjects aged 65 and over to determine whether they respond differently from younger subjects.  Other reported clinical experience has not identified differences in response between the elderly and younger patients.  In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS</span></h1>
<p class="First">The most common adverse reaction is <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> associated in several cases with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> and/or <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.  <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> has also been reported.  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> (caused by uterine contractions), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> have occurred occasionally.  Rarely observed reactions have included: <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, transient <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pains</span>, <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>, <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>, coronary <span class="product-label-link" type="condition" conceptid="4292397" conceptname="Arteriospasm">arterial spasm</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and foul taste.</p>
<p>There have been rare isolated reports of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, without a proven causal relationship to the drug product.</p>
<div class="Section">
<a name="section-7.1"></a><p></p>
<h2><span class="Bold">Postmarketing Experience</span></h2>
<p class="First">The following adverse drug reactions have been derived from post-marketing experience with methylergonovine maleate via spontaneous case reports. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorized as not known.</p>
</div>
<div class="Section">
<a name="section-7.2"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Cerebrovascular accident</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paraesthesia</span></p>
</div>
<div class="Section">
<a name="section-7.3"></a><p></p>
<h2><span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span></span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">Ventricular fibrillation</span>, <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-8"></a><p></p>
<h1><span class="Bold">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></span></h1>
<p class="First">Methylergonovine maleate has not been associated with drug abuse or <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> of either a physical or psychological nature.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1><span class="Bold">OVERDOSAGE</span></h1>
<p class="First">Symptoms of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span> may include:  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> of the extremities, <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">rise in blood pressure</span>, in severe cases followed by <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.</p>
<p>Because reports of overdosage with methylergonovine maleate are infrequent, the lethal dose in humans has not been established.  The oral LD<span class="Sub">50</span>(in mg/kg) for the mouse is 187, the rat 93, and the rabbit 4.5.  Several cases of accidental methylergonovine maleate injection in newborn infants have been reported, and in such cases 0.2 mg represents an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of great magnitude.  However, recovery occurred in all but one case following a period of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonicity</span> with jerking movements, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>.</p>
<p>Also, several children 1 to 3 years of age have accidentally ingested up to 10 tablets (2 mg) with no apparent ill effects. A postpartum patient took 4 tablets at one time in error and reported <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clamminess</span> as her only symptoms.</p>
<p>Treatment of acute overdosage is symptomatic and includes the usual procedures of:</p>
<ol class="Arabic">
<li>removal of offending drug by inducing <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, gastric lavage, catharsis, and supportive <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>.</li>
<li>maintenance of adequate pulmonary ventilation, especially if <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> develop.</li>
<li>correction of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> with pressor drugs as needed.</li>
<li>control of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> with standard anticonvulsant agents.</li>
<li>control of peripheral <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> with warmth to the extremities if needed.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-10"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION</span></h1>
<p class="First">Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.</p>
<div class="Section">
<a name="section-10.1"></a><p></p>
<h2><span class="Bold">Intramuscularly</span></h2>
<p class="First">1 mL, 0.2 mg, after delivery of the anterior shoulder, after delivery of the placenta, or during the puerperium.  May be repeated as required, at intervals of 2 to 4 hours.</p>
</div>
<div class="Section">
<a name="section-10.2"></a><p></p>
<h2><span class="Bold">Intravenously</span></h2>
<p class="First">1 mL, 0.2 mg, administered slowly over a period of no less than 60 seconds (See<a href="#b4122711-1141-4132-8ab3-e589472a8204">WARNINGS</a>.)</p>
</div>
<div class="Section">
<a name="section-10.3"></a><p></p>
<h2><span class="Bold">Orally</span></h2>
<p class="First">One tablet, 0.2 mg, 3 or 4 times daily in the puerperium for a maximum of 1 week.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED</span></h1>
<table frame="void" width="638"><tbody class="Headless"><tr class="First Last">
<td valign="top">NDC 0517-0740-20</td>
<td valign="top">0.2 mg/mL</td>
<td valign="top">1 mL Single Dose Vials </td>
<td valign="top">Packages of 20</td>
</tr></tbody></table>
<div class="Section">
<a name="section-11.1"></a><p></p>
<h2><span class="Bold">Store and Dispense</span></h2>
<p class="First">Store in refrigerator, 2º to 8ºC (36º to 46ºF).  Protect from light.  Use carton to protect contents until used.  Administer only if solution is clear and colorless.</p>
<p>Revised November 2012</p>
<p><span class="Bold">AMERICAN</span><span class="Bold"><br></span><span class="Bold">REGENT, INC.</span><span class="Bold"><br></span>SHIRLEY, NY 11967</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-12"></a><p></p>
<h1><span class="Bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</span></h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 1 mL Label</span></p>
<p>NDC 0517-0740-01</p>
<p><span class="Bold">METHYLERGONOVINE</span><span class="Bold"><br></span><span class="Bold">MALEATE</span><span class="Bold"><br></span>INJECTION, USP</p>
<p><span class="Bold">0.2 mg/mL</span></p>
<p><span class="Bold">1 mL</span></p>
<p>SINGLE DOSE VIAL</p>
<p><span class="Bold">FOR IM OR IV USE</span></p>
<p><span class="Bold">Rx Only</span></p>
<div class="Figure"><img alt="08d60c14-figure-02" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a9a3079e-b62b-4858-920e-d8f5cb38481e&amp;name=08d60c14-figure-02.jpg"></div>
<p><span class="Bold">PRINCIPAL DISPLAY PANEL - 1 mL Carton</span></p>
<p>NDC 0517-0740-20</p>
<p><span class="Bold">METHYLERGONOVINE</span><span class="Bold"><br></span><span class="Bold">MALEATE</span><span class="Bold"><br></span>INJECTION, USP</p>
<p><span class="Bold">0.2 mg/mL</span></p>
<p><span class="Bold">20 x 1 mL</span><span class="Bold"><br></span><span class="Bold">SINGLE DOSE VIALS</span></p>
<p><span class="Bold">FOR INTRAMUSCULAR OR</span><span class="Bold"><br></span><span class="Bold">INTRAVENOUS USE</span></p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">AMERICAN</span><span class="Bold"><br></span><span class="Bold">REGENT, INC.</span><span class="Bold"><br></span>SHIRLEY, NY  11967</p>
<dl>
<dt></dt>
<dd><p class="First"><img alt="08d60c14-figure-03" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a9a3079e-b62b-4858-920e-d8f5cb38481e&amp;name=08d60c14-figure-03.jpg"></p></dd>
</dl>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>METHYLERGONOVINE MALEATE 		
					</strong><br><span class="contentTableReg">methylergonovine maleate injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0517-0740</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS, INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METHYLERGONOVINE MALEATE</strong> (METHYLERGONOVINE) </td>
<td class="formItem">METHYLERGONOVINE MALEATE</td>
<td class="formItem">0.2 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MALEIC ACID</strong></td>
<td class="formItem">0.10 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">7.0 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0517-0740-20</td>
<td class="formItem">20  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0517-0740-01</td>
<td class="formItem">1 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA090193</td>
<td class="formItem">06/21/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>American Regent, Inc.
							(622781813)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Luitpold Pharmaceuticals, Inc. (002033710)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">PharmaForce, Inc.</td>
<td class="formItem"></td>
<td class="formItem">113894740</td>
<td class="formItem">ANALYSIS(0517-0740)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">PharmaForce, Inc.</td>
<td class="formItem"></td>
<td class="formItem">606821721</td>
<td class="formItem">MANUFACTURE(0517-0740)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>08d60c14-0e2b-4fa7-81d5-75f4320704d6</div>
<div>Set id: a9a3079e-b62b-4858-920e-d8f5cb38481e</div>
<div>Version: 2</div>
<div>Effective Time: 20130206</div>
</div>
</div> <div class="DistributorName">American Regent, Inc.</div></p>
</body></html>
